HUTCHMED (China)
HCM | NASDAQ
$14.73
-$0.17 (-1.14%)
At close: Nov 16, 2026, 4:00 PM ET
$14.73
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:10 PM ET
HUTCHMED (China) Company Profile
Company profile explainedCompany Profile
HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main areas: Oncology/Immunology and a segment encompassing Other Ventures. The company's reach extends from Hong Kong globally. Among its pipeline, HUTCHMED is developing Savolitinib, an inhibitor targeting non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Another key therapeutic, Fruquintinib, is an inhibitor being investigated for its efficacy in CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and a range of other gastrointestinal and solid tumors. Furthermore, the company's portfolio includes Surufatinib, an inhibitor applicable to numerous conditions such as neuroendocrine tumors (NETs - both pancreatic and non-pancreatic), biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, gastric cancer (GC), thyroid cancer, endometrial cancer (EMC), NSCLC, and general solid tumors. HMPL-523, a spleen tyrosine kinase inhibitor, is designed to treat hematological cancers and specific chronic immune conditions, while HMPL-689 targets the isoform PI3Kd (phosphoinositide 3'-kinase delta). Additional compounds in development include Tazemetostat, an EZH2 inhibitor indicated for specific epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor showing promise for hematological malignancies, gliomas, and solid tumors; HMPL-760, which functions as a Bruton's tyrosine kinase inhibitor; and HMPL-453, an inhibitor aimed at intrahepatic cholangiocarcinoma. The pipeline also features HMPL-295 for solid tumors, HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors, alongside Epitinib (HMPL-813) and Theliatinib (HMPL-309), both of which act as inhibitors. HUTCHMED maintains strategic collaboration agreements with a number of partners, including AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The entity, established in 2000 and headquartered in Central, Hong Kong, was previously identified as Hutchison China MediTech Limited before officially adopting its current name, HUTCHMED (China) Limited, in May 2021.
Key Executives
| Name | Position |
|---|---|
| Chig Fung Cheng | Acting Chief Executive Officer, Chief Financial Officer & Executive Director |
| Weiguo Su | Chief Executive Officer, Chief Scientific Officer & Executive Director (Leave of Absence) |
| Charles George Rupert Nixon | Group General Counsel |
| David Ng | Head of Investor Relations & Capital Strategies |
| Kin Hung Lee | Senior Vice President of Corporate Management & Communications |
| Qingmei Wang | Executive Vice President of Business Development & Strategic Alliances |
| Selina Zhang | Senior Vice President of Global Human Resources |
| Thomas Fu | Senior Vice President of Global Quality |
| Xinhui Hu | Executive Vice President & Chief Technical Officer |
| Yiling Cui | Executive Vice President & Head of Operations |
HUTCHMED (China)
| Country | Hong Kong SAR China |
| IPO Date | Mar 16, 2016 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,796 |
| CEO | Chig Fung Cheng |
Contact Details
Cheung Kong Center Hong Kong Hong Kong SAR China
Stock Details
| Ticker Symbol | HCM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001648257 |
| CUSIP Number | 44842L103 |
| ISIN Number | US44842L1035 |
| SIC Code | 2834 |
Recent News
- 1 day ago / globenewswire.comHUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®
- 4 days ago / seekingalpha.comHUTCHMED (China) Limited (HCM) Presents at Deutsche Bank Virtual Investor Conference Transcript
- 6 days ago / globenewswire.comBraveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
- 12 days ago / prnewswire.comEdgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring
- 12 days ago / globenewswire.comHUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
- 15 days ago / globenewswire.comHUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
- 18 days ago / globenewswire.comBraveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026
- 19 days ago / globenewswire.comHUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
- 21 days ago / globenewswire.comSave the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
- 22 days ago / globenewswire.comHUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
Add to Watchlist
Select watchlists to add or remove HCM